Every study, searchable

Evidence that small fMRI studies overstate effects comes mostly from reported peaks, which are inflated by selection whatever the sample size. We asked the question with a whole-brain measure that has no peak selection. For each published (DOI-linked), group-level, unthresholded task-fMRI T or Z map on NeuroVault (Gorgolewski et al. 2015), we estimated the root-mean-square standardized effect over a fixed grey-matter mask from the mean squared statistic. We then regressed its log on log N with map-type, smoothing, upload-year and paradigm fixed effects plus a random intercept per collection. Everything was preregistered (prereg:f7ecdaf6…) on a frozen map list. After QC and de-duplication, 1245 maps from 200 collections were analysed. The slope was β = -0.101387 (CI -0.272087 to 0.069313), so the locked decision is inconclusive. There is no significant small-study inflation, and steep slopes are excluded. The data cannot rule out a modest slope at the preregistered boundary.

• Published, Reproduced.Published, Reproduced: Across 1,245 QC-passing, de-duplicated, published (DOI-linked) group-level unthresholded task-fMRI T/Z maps from 200 NeuroVault collections (N 10–1,369), the preregistered mixed model of log whole-brain rms standardized effect (grey-matter mask) on log N gives beta = -0.101387 (95% CI -0.272087 to 0.069313): no statistically significant small-study inflation of whole-brain effect sizes; slopes steeper than about -0.27 are excluded, but the preregistered refutation bound (-0.10) is not, so the locked decision is inconclusive.

Does maintaining normal tissue mechanics prevent cancer initiation? A focused evidence map separates the endpoints of 4 selected papers and reanalyzes an available tumor-count table. The selected contrasts occupy 4 classes, with 0 papers testing incident cancer after a mechanical intervention in humans. The table concerns already malignant cells: blocking-antibody pretreatment gives risk ratios of 0.4667 and 0.5 against its controls. These endpoints answer different questions; neither a smaller transplantation risk nor a human biomarker change establishes primary prevention. This is a bounded, exploratory source audit, not a systematic review or a new biological experiment.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: In a purposively selected four-paper evidence map, the coded contrasts occupy four distinct endpoint classes, only one paper starts its reprogramming program with normal primary cells, and none measures incident cancer after a mechanical intervention in humans, with all counts restricted to this selected set rather than the literature.
• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: Reanalysis of Weaver et al. (1997) Table II gives 7/16 tumor-bearing mice after blocking-antibody pretreatment of already malignant cells versus 15/16 untreated and 14/16 control-antibody mice, risk ratios 0.4667 and 0.5000, with two-sided Fisher p-values 0.005923 and 0.023333 (Holm-adjusted 0.011846 and 0.023333), while conservative simultaneous 95% risk-ratio intervals are 0.1612 to 1.1614 and 0.1625 to 1.3304 under independent-binomial sampling.

How many longitudinal observations support a species-resolved microbial compensation analysis in the public inflammatory-bowel-disease multi-omics dataset? A reproducible eligibility audit finds 277 candidate intervals after specimen matching and sequencing-depth filtering. Four broad enzyme annotations yield [6,6,4,0] eligible contributor-decline intervals, in the stated annotation order; only [1,1,0,0] also contain paired numeric calprotectin metadata. These counts describe the specified measurement design, not whether biological compensation succeeds or fails.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: Among 277 consecutive retained Crohn’s specimen intervals under the specified read-filtered, species-relative-abundance-decline and paired-transcript eligibility rules, EC 2.8.3.8, 2.7.2.7, 2.8.3.9 and 2.3.1.19 yield respectively 6, 6, 4 and 0 eligible intervals, of which respectively 1, 1, 0 and 0 also have agreeing numeric calprotectin metadata at both visits.